BIONEWS
Argenx moves from April investor to outright acquirer of Forte Biosciences, paying $2.2B for its early vitiligo and celiac antibody. A larger celiac trial later this year will show whether the bet holds.
Three months after writing a check into Forte Biosciences' $150M public offering, Argenx agreed on Monday to buy the whole company for $2.2B. The fast escalation from one of several strategic investors to sole acquirer is the most under-read part of the deal.
Argenx, a commercial-stage immunology company built around the rare-disease drug Vyvgart, is paying for FB102, an antibody that targets a specific receptor on the immune cells that drive autoimmune damage. What Argenx is buying, in plain terms, is a single molecule that has produced its first meaningful human results in two different diseases: vitiligo, a skin-depigmentation condition with limited treatment options, and celiac disease, an autoimmune reaction to gluten.
The case for paying up rests on a small Phase Ib trial in vitiligo that read out earlier this month. Forte reported that patients on FB102 saw a roughly 30% improvement on the standard facial vitiligo score at 24 weeks, a result that crossed the bar for statistical significance. In a subgroup with more extensive disease at baseline, the improvement reached 43% (Forte press release via GlobeNewswire).
The trial enrolled a modest number of patients and ran only to week 24, so the durability of the response beyond that window is still unproven. The vitiligo field has seen late-stage failures, and any clean comparison to the leading topical drug, Incyte's Opzelura, will require a larger study (Clinical Trials Arena coverage).
That larger study, in celiac disease, is the next hard checkpoint. Forte reported positive Phase Ib data in celiac in 2025, and a Phase II readout is expected in the second half of this year. If that trial misses, the $2.2B price tag will look, in retrospect, like a strategic overreach for a single early-stage asset. If it hits, FB102 becomes the centerpiece of an argument that one antibody can treat a family of autoimmune diseases driven by the same immune-cell pathway (AllSci coverage of durable post-treatment gains).
The investor-to-acquirer history is the part the wire will not spell out. Argenx participated in Forte's $150M April public offering, buying 5.7 million shares at $26.27. That put a named strategic investor inside the company less than 90 days before the buyout. Argenx disclosed the transaction in a joint release and filed a material-event notice with the SEC; Argenx CEO Karen Massey framed the deal as a fit with the company's "playbook" of compelling biology, strong clinical validation, and broad patient reach (GEN analysis; Forte 8-K filing).
The $2.2B price is also a marker for M&A appetite in autoimmune disease. A takeout of a single-asset, Phase Ib-stage biotech at this level shows how aggressively strategic acquirers are pricing multi-indication optionality. Forte is the marker; the celiac readout later this year is the test.